^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQ-B3456

    i
    Other names: TQ-B3456, TQB3456
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics (clinicaltrials.gov)
    P1, N=1, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=50 --> 1 | Trial completion date: May 2020 --> Feb 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2022; The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    TQ-B3456